BioMarin Pharmaceutical stock falls 1.38 percent on Nasdaq

Published on 09/25/2026 at 08:29 | Editorial responsibility: Rafael Müller, Editor-in-Chief AD HOC NEWS

BioMarin Pharmaceutical stock traded at USD 61.35 on September 24, 2026, 13.6 percent below its 52-week high. Q2 revenue reached USD 990 million, up 20 percent year over year.

BMRN, US09061G1013, Illustration mit AI erstellt.

BioMarin Pharmaceutical stock (ISIN US09061G1013) fell 1.38 percent to USD 61.35 on Nasdaq at the September 24, 2026 close. The move leaves the stock 13.6 percent below its 52-week high of USD 70.98, while the company is balancing strong quarterly growth against a setback for one VOXZOGO program.

VOXZOGO program changes

BioMarin discontinued development of VOXZOGO for children with Noonan syndrome on September 15, 2026, citing study feasibility and the treatment landscape rather than safety or efficacy, according to Stock Titan.

The decision contrasts with the September 9, 2026 report of positive Phase 3 results for VOXZOGO in children with hypochondroplasia. After 52 weeks, annualized growth velocity improved by 2.33 centimeters per year versus placebo, according to finanzen.at.

Revenue growth meets guidance

BioMarin generated USD 990 million in Q2 2026 revenue, a 20 percent year-over-year increase. The figure exceeded the USD 932.03 million consensus estimate by USD 57.68 million, while quarterly earnings reached USD 1.20 per share against USD 0.95 expected, according to MarketBeat.

The same Q2 report showed GAAP net income of USD 45 million, compared with USD 241 million in the year-earlier quarter. BioMarin maintained fiscal 2026 non-GAAP diluted EPS guidance of USD 4.90 to USD 5.10, giving the stock a clear earnings benchmark despite the uneven clinical news flow.

Stock remains below yearly high

BioMarin's market capitalization was USD 11.86 billion on September 24, 2026. The stock's 52-week range was USD 49.26 to USD 70.98, placing the latest close closer to the upper end than the yearly low but still 13.6 percent below the high.

The closing price was USD 61.35 on Nasdaq on September 24, 2026, down USD 0.86 or 1.38 percent for the session. For investors, the central balance is clear: Q2 revenue beat consensus by USD 57.68 million, while development decisions remain important for the pipeline's future commercial reach.